Skip to main content

Healthy Adult Males Volunteers

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Menarini
MenariniGermany - Dresden
1 program
1
TamsulosinPhase 11 trial
Active Trials
NCT07146711Active Not Recruiting33Est. Dec 2025
Berlin-Chemie
Berlin-ChemieGermany - Berlin
1 program
1
TamsulosinPhase 1
Santen
SantenCA - Emeryville
1 program
STN1012600 ophthalmic solution 0.002%PHASE_11 trial
Active Trials
NCT05905653Completed8Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
MenariniTamsulosin
SantenSTN1012600 ophthalmic solution 0.002%

Clinical Trials (2)

Total enrollment: 41 patients across 2 trials

A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

Start: Mar 2025Est. completion: Dec 202533 patients
Phase 1Active Not Recruiting
NCT05905653SantenSTN1012600 ophthalmic solution 0.002%

Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Start: May 2023Est. completion: Jun 20238 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.